Enveric Biosciences Inc (ENVB NASDAQ) stock market data APIs
$1.3517
-0.05(-3.7%)
as of June 23, 2026
Try our APIs with
free plan!
Enveric Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Prev. Close
1.3517
Open
1.3004
High
1.4224
Low
1.2969
52 wk Range
1.26-17.64
Market Cap
5 358 K
Shares Outstanding
4 028 K
Revenue
35 405 K
EPS
-1.0815
Beta
1.096
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enveric Biosciences Inc data using free add-ons & libraries
Get Enveric Biosciences Inc Fundamental Data
Enveric Biosciences Inc Fundamental data includes:
- Net Revenue: 35 405 K
- EBITDA: -8 063 011
- Earnings Per Share: -22
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-19
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enveric Biosciences Inc News
New
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Product Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial Reported additional preclinical data...
Stock market today: S&P 500, Nasdaq, Dow edge lower as US-Iran tensions flare up again, shuttering Hormuz
US stocks fell on Monday after a chaotic weekend of events reignited US-Iran tensions, putting peace talks at risk and leaving investors bracing for more uncertainty. The S&P 500 (^GSPC) shed 0.1%, w...
Enveric Biosciences targets up to $13.9M in total proceeds via share and warrant offering
Enveric Biosciences (ENVB [https://seekingalpha.com/symbol/ENVB]) has announced its agreement to sell 2.22M shares [https://seekingalpha.com/pr/20477201-enveric-biosciences-announces-up-to-13_9-millio...
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and ...
Get Enveric Biosciences Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
